Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which ...

Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by ...

Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to eliminate 114 positions ...

Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. | ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS secretary ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

Iterum took its time launching Orlynvah, debuting the drug in August 2025, almost a full year after securing approval. That ...

Forget March going out like a lamb. On the M&A landscape, March went out like a lion.  | In a flurry of activity, biopharma ...

Japan’s Shionogi is joining the spate of drugmakers to announce manufacturing commitments in the U.S. since last year, albeit ...

For more than a year, the biopharma industry has had to swiftly react to various tariff threats from the Trump administration. | The president has rolled out a 100% tariff rate on patented ...